Postsurgical management of differentiated thyroid carcinoma.
This article identifies the important prognostic factors that determine outcome and medical management of papillary and follicular thyroid cancer. It summarizes current trends in the use of radioactive iodine (131I) and gives explicit advice on its use in the treatment of these cancers. Preparation, dosimetry, and complication of therapy are discussed in detail. Follow-up with measurement of serum thyroglobulin concentrations and subsequent treatment with thyroid hormone is reviewed.
Mazzaferri
E L
EL
Department of Internal Medicine, Ohio State University, Columbus, USA.
Robyn
J
J
D018263:Adenocarcinoma, Follicular / Q000601:surgery*; D002291:Carcinoma, Papillary / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D005500:Follow-Up Studies; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use; D011182:Postoperative Care; D011379:Prognosis; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D013954:Thyroglobulin / Q000097:blood; D013963:Thyroid Hormones / Q000627:therapeutic use; D013964:Thyroid Neoplasms / Q000601:surgery*; D013965:Thyroidectomy; D016896:Treatment Outcome
D007457:Iodine Radioisotopes; D013963:Thyroid Hormones; D013954:Thyroglobulin